首页 > 最新文献

Current Hypertension Reviews最新文献

英文 中文
Targeting Hypertension: A Review on Pathophysiological Factors and Treatment Strategies. 针对高血压:病理生理因素和治疗策略综述》。
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021293403240309165336
Ruhani Raj, Minakshi Garg, Anupreet Kaur

Hypertension is one of the primary causes of cardiovascular diseases and death, with a higher prevalence in low- and middle-income countries. The pathophysiology of hypertension remains complex, with 2% to 5% of patients having underlying renal or adrenal disorders. The rest are referred to as essential hypertension, with derangements in various physiological mechanisms potentially contributing to the development of essential hypertension. Hypertension elevates the risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and mortality. First-line therapy for hypertension is lifestyle change, which includes weight loss, a balanced diet that includes low salt and high potassium intake, physical exercise, and limitation or elimination of alcohol use. Blood pressure-lowering effects of individual lifestyle components are partially additive, enhancing the efficacy of pharmaceutical treatment. The choice to begin antihypertensive medication should be based on the level of blood pressure and the existence of a high atherosclerotic CVD risk. First-line hypertension treatment includes a thiazide or thiazide-like diuretic, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and a calcium channel blocker. Addressing hypertension will require continued efforts to improve access to diagnosis, treatment, and lifestyle interventions.

高血压是心血管疾病和死亡的主要原因之一,在中低收入国家发病率较高。高血压的病理生理学仍然很复杂,2% 至 5%的患者有潜在的肾脏或肾上腺疾病。其余患者被称为本质性高血压,各种生理机制的失调都可能导致本质性高血压的发生。高血压会增加心血管疾病(CVD)事件(冠心病、心力衰竭和中风)和死亡的风险。高血压的一线疗法是改变生活方式,包括减轻体重、摄入低盐高钾的均衡饮食、体育锻炼、限制或戒酒。各种生活方式的降压作用具有部分相加性,可增强药物治疗的疗效。应根据血压水平和是否存在高动脉粥样硬化性心血管疾病风险来选择是否开始服用降压药。一线高血压治疗包括噻嗪类或噻嗪类利尿剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂以及钙通道阻滞剂。要解决高血压问题,就必须继续努力改善诊断、治疗和生活方式干预。
{"title":"Targeting Hypertension: A Review on Pathophysiological Factors and Treatment Strategies.","authors":"Ruhani Raj, Minakshi Garg, Anupreet Kaur","doi":"10.2174/0115734021293403240309165336","DOIUrl":"10.2174/0115734021293403240309165336","url":null,"abstract":"<p><p>Hypertension is one of the primary causes of cardiovascular diseases and death, with a higher prevalence in low- and middle-income countries. The pathophysiology of hypertension remains complex, with 2% to 5% of patients having underlying renal or adrenal disorders. The rest are referred to as essential hypertension, with derangements in various physiological mechanisms potentially contributing to the development of essential hypertension. Hypertension elevates the risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and mortality. First-line therapy for hypertension is lifestyle change, which includes weight loss, a balanced diet that includes low salt and high potassium intake, physical exercise, and limitation or elimination of alcohol use. Blood pressure-lowering effects of individual lifestyle components are partially additive, enhancing the efficacy of pharmaceutical treatment. The choice to begin antihypertensive medication should be based on the level of blood pressure and the existence of a high atherosclerotic CVD risk. First-line hypertension treatment includes a thiazide or thiazide-like diuretic, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and a calcium channel blocker. Addressing hypertension will require continued efforts to improve access to diagnosis, treatment, and lifestyle interventions.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"70-79"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update. 内皮功能障碍发病机制中的黄嘌呤氧化还原酶:最新进展。
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021277772240124075120
Rajat Mudgal, Sanjiv Singh

Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in the formation of uric acid (UA) and is involved in the generation of reactive oxygen species (ROS). Overproduction of ROS has been linked to the pathogenesis of hypertension, atherosclerosis, and cardiovascular disease, with multiple studies over the last 30 years demonstrating that XOR inhibition is beneficial. The involvement of XOR and its constituents in the advancement of chronic inflammation and ROS, which are responsible for endothelial dysfunction, is the focus of this evidence-based review. An overabundance of XOR products and ROS appears to drive the inflammatory response, resulting in significant endothelium damage. It has also been demonstrated that XOR activity and ED are connected. Diabetes, hypertension, and cardiovascular disease are all associated with endothelial dysfunction. ROS mainly modifies the activity of vascular cells and can be important in normal vascular physiology as well as the development of vascular disease. Suppressing XOR activity appears to decrease endothelial dysfunction, probably because it lessens the generation of reactive oxygen species and the oxidative stress brought on by XOR. Although there has long been a link between higher vascular XOR activity and worse clinical outcomes, new research suggests a different picture in which positive results are mediated by XOR enzymatic activity. Here in this study, we aimed to review the association between XOR and vascular endothelial dysfunction. The prevention and treatment approaches against vascular endothelial dysfunction in atherosclerotic disease.

黄嘌呤氧化还原酶(XOR)是尿酸(UA)形成过程中的一种限速酶,并参与活性氧(ROS)的生成。ROS 的过度产生与高血压、动脉粥样硬化和心血管疾病的发病机制有关,过去 30 年的多项研究表明,抑制 XOR 对人体有益。XOR 及其成分参与了慢性炎症和 ROS 的发展,而慢性炎症和 ROS 是导致内皮功能障碍的罪魁祸首,这是本循证综述的重点。过量的 XOR 产物和 ROS 似乎推动了炎症反应,导致内皮严重受损。研究还证明,XOR 活性与 ED 有关。糖尿病、高血压和心血管疾病都与内皮功能障碍有关。ROS 主要改变血管细胞的活性,在正常的血管生理和血管疾病的发展中都很重要。抑制 XOR 的活性似乎能减少内皮功能障碍,这可能是因为它能减少活性氧的生成和 XOR 带来的氧化应激。虽然血管中较高的 XOR 活性与较差的临床结果之间一直存在联系,但新的研究表明,积极的结果是由 XOR 酶活性介导的。在本研究中,我们旨在回顾 XOR 与血管内皮功能障碍之间的关联。动脉粥样硬化性疾病血管内皮功能障碍的预防和治疗方法。
{"title":"Xanthine Oxidoreductase in the Pathogenesis of Endothelial Dysfunction: An Update.","authors":"Rajat Mudgal, Sanjiv Singh","doi":"10.2174/0115734021277772240124075120","DOIUrl":"10.2174/0115734021277772240124075120","url":null,"abstract":"<p><p>Xanthine oxidoreductase (XOR) is a rate-limiting enzyme in the formation of uric acid (UA) and is involved in the generation of reactive oxygen species (ROS). Overproduction of ROS has been linked to the pathogenesis of hypertension, atherosclerosis, and cardiovascular disease, with multiple studies over the last 30 years demonstrating that XOR inhibition is beneficial. The involvement of XOR and its constituents in the advancement of chronic inflammation and ROS, which are responsible for endothelial dysfunction, is the focus of this evidence-based review. An overabundance of XOR products and ROS appears to drive the inflammatory response, resulting in significant endothelium damage. It has also been demonstrated that XOR activity and ED are connected. Diabetes, hypertension, and cardiovascular disease are all associated with endothelial dysfunction. ROS mainly modifies the activity of vascular cells and can be important in normal vascular physiology as well as the development of vascular disease. Suppressing XOR activity appears to decrease endothelial dysfunction, probably because it lessens the generation of reactive oxygen species and the oxidative stress brought on by XOR. Although there has long been a link between higher vascular XOR activity and worse clinical outcomes, new research suggests a different picture in which positive results are mediated by XOR enzymatic activity. Here in this study, we aimed to review the association between XOR and vascular endothelial dysfunction. The prevention and treatment approaches against vascular endothelial dysfunction in atherosclerotic disease.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"10-22"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of COVID-19 and Arterial Stiffness Assessed using Cardiovascular Index (CAVI). COVID-19 与心血管指数(CAVI)评估的动脉僵硬度之间的关系。
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021279173240110095037
Valery Podzolkov, Anna Bragina, Aida Tarzimanova, Lyubov Vasilyeva, Ilya Shvedov, Natalya Druzhinina, Yulia Rodionova, Tatiana Ishina, Iuliia Akyol, Valentina Maximova, Alexandr Cherepanov

Background: COVID-19 is characterized by an acute inflammatory response with the formation of endothelial dysfunction and may affect arterial stiffness. Studies of cardio-ankle vascular index in COVID-19 patients with considered cardiovascular risk factors have not been conducted.

Objective: The purpose of our study was to assess the association between cardio-ankle vascular index and COVID-19 in hospitalized patients adjusted for known cardiovascular risk factors.

Methods: A cross-sectional study included 174 people hospitalized with a diagnosis of moderate COVID-19 and 94 people without COVID-19. Significant differences in the cardio-ankle vascular index values measured by VaSera VS - 1500N between the two groups were analyzed using parametric (Student's t-criterion) and nonparametric (Mann-Whitney) criteria. Independent association between COVID-19 and an increased cardio-ankle vascular index ≥ 9.0 adjusted for known cardiovascular risk factors was assessed by multivariate logistic regression.

Results: There were significantly higher values of the right cardio-ankle vascular index 8.10 [7.00;9.40] and the left cardio-ankle vascular index 8.10 [6.95;9.65] in patients undergoing inpatient treatment for COVID-19 than in the control group - 7.55 [6.60;8.60] and 7.60 [6.60;8.70], respectively. A multivariate logistic regression model adjusted for age, hypertension, plasma glucose level, glomerular filtration rate and diabetes mellitus showed a significant association between increased cardio-ankle vascular index and COVID-19 (OR 2.41 [CI 1.09;5.30]).

Conclusion: Hospitalized patients with COVID-19 had significantly higher cardio-ankle vascular index values compared to the control group. An association between an increased cardio-ankle vascular index and COVID-19 was revealed, independent of age, hypertension, plasma glucose level, glomerular filtration rate and diabetes mellitus.

背景:COVID-19 以急性炎症反应为特征,会形成内皮功能障碍,并可能影响动脉僵化。目前尚未对具有心血管风险因素的 COVID-19 患者的心踝关节血管指数进行研究:我们的研究旨在评估住院患者的心踝关节血管指数与 COVID-19 之间的关系,并对已知的心血管风险因素进行调整:一项横断面研究纳入了174名被诊断为中度COVID-19的住院患者和94名没有COVID-19的患者。采用参数(学生 t 标准)和非参数(Mann-Whitney)标准分析了两组患者通过 VaSera VS - 1500N 测量的心踝关节血管指数值的显著差异。通过多变量逻辑回归评估了 COVID-19 与已知心血管风险因素调整后的心踝关节血管指数≥9.0 之间的独立关联:结果:接受COVID-19住院治疗的患者右侧心踝关节血管指数为8.10 [7.00;9.40],左侧心踝关节血管指数为8.10 [6.95;9.65],明显高于对照组,分别为7.55 [6.60;8.60]和7.60 [6.60;8.70]。经年龄、高血压、血浆葡萄糖水平、肾小球滤过率和糖尿病调整的多变量逻辑回归模型显示,心踝关节血管指数增加与 COVID-19 有显著关联(OR 2.41 [CI 1.09;5.30]):结论:与对照组相比,COVID-19住院患者的心踝关节血管指数值明显更高。结论:与对照组相比,COVID-19住院患者的心踝关节血管指数值明显较高,表明心踝关节血管指数升高与COVID-19之间存在关联,与年龄、高血压、血浆葡萄糖水平、肾小球滤过率和糖尿病无关。
{"title":"Association of COVID-19 and Arterial Stiffness Assessed using Cardiovascular Index (CAVI).","authors":"Valery Podzolkov, Anna Bragina, Aida Tarzimanova, Lyubov Vasilyeva, Ilya Shvedov, Natalya Druzhinina, Yulia Rodionova, Tatiana Ishina, Iuliia Akyol, Valentina Maximova, Alexandr Cherepanov","doi":"10.2174/0115734021279173240110095037","DOIUrl":"10.2174/0115734021279173240110095037","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 is characterized by an acute inflammatory response with the formation of endothelial dysfunction and may affect arterial stiffness. Studies of cardio-ankle vascular index in COVID-19 patients with considered cardiovascular risk factors have not been conducted.</p><p><strong>Objective: </strong>The purpose of our study was to assess the association between cardio-ankle vascular index and COVID-19 in hospitalized patients adjusted for known cardiovascular risk factors.</p><p><strong>Methods: </strong>A cross-sectional study included 174 people hospitalized with a diagnosis of moderate COVID-19 and 94 people without COVID-19. Significant differences in the cardio-ankle vascular index values measured by VaSera VS - 1500N between the two groups were analyzed using parametric (Student's t-criterion) and nonparametric (Mann-Whitney) criteria. Independent association between COVID-19 and an increased cardio-ankle vascular index ≥ 9.0 adjusted for known cardiovascular risk factors was assessed by multivariate logistic regression.</p><p><strong>Results: </strong>There were significantly higher values of the right cardio-ankle vascular index 8.10 [7.00;9.40] and the left cardio-ankle vascular index 8.10 [6.95;9.65] in patients undergoing inpatient treatment for COVID-19 than in the control group - 7.55 [6.60;8.60] and 7.60 [6.60;8.70], respectively. A multivariate logistic regression model adjusted for age, hypertension, plasma glucose level, glomerular filtration rate and diabetes mellitus showed a significant association between increased cardio-ankle vascular index and COVID-19 (OR 2.41 [CI 1.09;5.30]).</p><p><strong>Conclusion: </strong>Hospitalized patients with COVID-19 had significantly higher cardio-ankle vascular index values compared to the control group. An association between an increased cardio-ankle vascular index and COVID-19 was revealed, independent of age, hypertension, plasma glucose level, glomerular filtration rate and diabetes mellitus.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"44-51"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11092554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139520117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Novelty of using Obesity Indices as Blood Pressure Predictors. 用肥胖指数作为血压预测指标的新颖性。
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021277171231114103758
Buthaina Alkhatib, Lana M Agraib, Islam Al-Shami, Anfal Al-Dalaeen

Aims: To study the association between selected obesity indices, systolic blood pressure (SBP), and diastolic blood pressure (DBP).

Methods: A cross-sectional study on 491 Jordanian adults (19-65 years old). The sociodemographic data, anthropometrics, and blood pressure were measured and recorded. Obesity indices (Conicity Index (CI), Abdominal volume index (AVI), Body Roundness Index (BRI), and Weight-adjusted-waist index (WWI)) were calculated using standard validated formulas.

Results: Based on age, the SBP had a significant moderate correlation with BRI and AVI in all age groups. In the age group 20 to 34 years, SBP had a significantly moderate correlation with CI, and DBP had a significantly moderate correlation with BRI and AVI. In the age group 35 to 44 years, DBP had a significantly moderate correlation with CI, BRI, WWI, and AVI. For the age group 45 to 65 years, the SBP had a significantly moderate correlation with all the obesity indexes, opposite to DBP. Obesity indices explain 23.6% to 24.1% of the changeability in SBP, and one unit increase in them resulted in an increase in SBP range from 0.61 ± 0.14 to 19.88 ± 4.45. For DBP, obesity indices explained 15.9% to 16.3% of the variability in DBP, and raising them by one unit led to an increase in the DBP range from 0.27 ± 0.11 to 10.08 ± 4.83.

Conclusion: All the studied obesity indices impacted SBP and DBP with the highest reported effect for AVI and BRI and a lower impact for WWI. The impact of obesity indices on DBP was affected by age group.

目的:研究肥胖指标与收缩压(SBP)和舒张压(DBP)的关系。方法:对491名约旦成年人(19-65岁)进行横断面研究。测量并记录社会人口统计数据、人体测量数据和血压。肥胖指数(圆锥度指数(CI)、腹部体积指数(AVI)、身体圆度指数(BRI)和体重调整腰围指数(WWI))采用标准验证公式计算。结果:基于年龄,所有年龄组的收缩压与BRI和AVI均有显著的中度相关。在20 ~ 34岁年龄组中,收缩压与CI有显著的中度相关性,舒张压与BRI和AVI有显著的中度相关性。在35 ~ 44岁年龄组中,DBP与CI、BRI、WWI和AVI有显著的中度相关。在45 ~ 65岁年龄组中,收缩压与所有肥胖指标均有显著的中度相关性,与舒张压相反。肥胖指数对收缩压变化的解释为23.6% ~ 24.1%,每增加1个单位,收缩压升高范围为0.61±0.14 ~ 19.88±4.45。对于舒张压,肥胖指数解释了15.9%至16.3%的舒张压变异性,每增加一个单位,舒张压范围从0.27±0.11增加到10.08±4.83。结论:所有肥胖指标均影响收缩压和舒张压,其中AVI和BRI的影响最大,WWI的影响较小。肥胖指标对舒张压的影响存在年龄组差异。
{"title":"The Novelty of using Obesity Indices as Blood Pressure Predictors.","authors":"Buthaina Alkhatib, Lana M Agraib, Islam Al-Shami, Anfal Al-Dalaeen","doi":"10.2174/0115734021277171231114103758","DOIUrl":"10.2174/0115734021277171231114103758","url":null,"abstract":"<p><strong>Aims: </strong>To study the association between selected obesity indices, systolic blood pressure (SBP), and diastolic blood pressure (DBP).</p><p><strong>Methods: </strong>A cross-sectional study on 491 Jordanian adults (19-65 years old). The sociodemographic data, anthropometrics, and blood pressure were measured and recorded. Obesity indices (Conicity Index (CI), Abdominal volume index (AVI), Body Roundness Index (BRI), and Weight-adjusted-waist index (WWI)) were calculated using standard validated formulas.</p><p><strong>Results: </strong>Based on age, the SBP had a significant moderate correlation with BRI and AVI in all age groups. In the age group 20 to 34 years, SBP had a significantly moderate correlation with CI, and DBP had a significantly moderate correlation with BRI and AVI. In the age group 35 to 44 years, DBP had a significantly moderate correlation with CI, BRI, WWI, and AVI. For the age group 45 to 65 years, the SBP had a significantly moderate correlation with all the obesity indexes, opposite to DBP. Obesity indices explain 23.6% to 24.1% of the changeability in SBP, and one unit increase in them resulted in an increase in SBP range from 0.61 ± 0.14 to 19.88 ± 4.45. For DBP, obesity indices explained 15.9% to 16.3% of the variability in DBP, and raising them by one unit led to an increase in the DBP range from 0.27 ± 0.11 to 10.08 ± 4.83.</p><p><strong>Conclusion: </strong>All the studied obesity indices impacted SBP and DBP with the highest reported effect for AVI and BRI and a lower impact for WWI. The impact of obesity indices on DBP was affected by age group.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"36-43"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension Management in Peripheral Artery Disease: A Mini Review. 外周动脉疾病的高血压管理:微型综述。
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021267004231122061712
A Kharawala, S Nagraj, S Pargaonkar, J Seo, D G Kokkinidis, S E Altin

Lower extremity peripheral artery disease (PAD) affects over 230 million adults globally, with hypertension being one of the major risk factors for the development of PAD. Despite the high prevalence, patients with hypertension who have concomitant PAD are less likely to receive adequate therapy. Through this review, we present the current evidence underlying hypertension management in PAD, guideline-directed therapies, and areas pending further investigation. Multiple studies have shown that both high and relatively lower blood pressure levels are associated with worse health outcomes, including increased morbidity and mortality. Hence, guideline-directed recommendation involves cautious management of hypertensive patients with PAD while ensuring hypotension does not occur. Although any antihypertensive medication can be used to treat these patients, the 2017 American Heart Association/American College of Cardiology (AHA/ACC), 2017 European Society of Cardiology (ESC), and 2022 Canadian guidelines favor the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) as the initial choice. Importantly, data on blood pressure targets and treatment of hypertension in PAD are limited and largely stem from sub-group studies and post-hoc analysis. Large randomized trials in patients with PAD are required in the future to delineate hypertension management in this complex patient population.

全球有超过 2.3 亿成年人患有下肢外周动脉疾病(PAD),而高血压是 PAD 发病的主要风险因素之一。尽管发病率很高,但同时患有 PAD 的高血压患者接受适当治疗的可能性较低。通过这篇综述,我们介绍了 PAD 中高血压管理的现有证据、指南指导疗法以及有待进一步研究的领域。多项研究表明,高血压和相对较低的血压水平都与较差的健康状况有关,包括发病率和死亡率的增加。因此,指南指导建议对患有 PAD 的高血压患者进行谨慎管理,同时确保不会发生低血压。虽然任何降压药物都可用于治疗这些患者,但 2017 年美国心脏协会/美国心脏病学会(AHA/ACC)、2017 年欧洲心脏病学会(ESC)和 2022 年加拿大指南均赞成将血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)作为初始选择。重要的是,有关 PAD 患者血压目标值和高血压治疗的数据非常有限,且主要来自亚组研究和事后分析。未来需要对 PAD 患者进行大规模的随机试验,以确定这一复杂患者群体的高血压治疗方法。
{"title":"Hypertension Management in Peripheral Artery Disease: A Mini Review.","authors":"A Kharawala, S Nagraj, S Pargaonkar, J Seo, D G Kokkinidis, S E Altin","doi":"10.2174/0115734021267004231122061712","DOIUrl":"10.2174/0115734021267004231122061712","url":null,"abstract":"<p><p>Lower extremity peripheral artery disease (PAD) affects over 230 million adults globally, with hypertension being one of the major risk factors for the development of PAD. Despite the high prevalence, patients with hypertension who have concomitant PAD are less likely to receive adequate therapy. Through this review, we present the current evidence underlying hypertension management in PAD, guideline-directed therapies, and areas pending further investigation. Multiple studies have shown that both high and relatively lower blood pressure levels are associated with worse health outcomes, including increased morbidity and mortality. Hence, guideline-directed recommendation involves cautious management of hypertensive patients with PAD while ensuring hypotension does not occur. Although any antihypertensive medication can be used to treat these patients, the 2017 American Heart Association/American College of Cardiology (AHA/ACC), 2017 European Society of Cardiology (ESC), and 2022 Canadian guidelines favor the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) as the initial choice. Importantly, data on blood pressure targets and treatment of hypertension in PAD are limited and largely stem from sub-group studies and post-hoc analysis. Large randomized trials in patients with PAD are required in the future to delineate hypertension management in this complex patient population.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synchronous Bilateral Brachial Blood Pressure Measurements Increased Orthostatic Hypotension Detection in the Elderly. 同步双侧肱动脉血压测量可提高对老年人直立性低血压的检测。
IF 2.3 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021269751231204114902
Jianying Zhang, Xia Gao, Benxu Ma, Lili Liu, Huanmin Gao

Background: Orthostatic hypotension (OH) is a common clinical sign, but its detection rate is low, and it is difficult to repeat because there is no standardized screening method available.

Aim: This study aimed to establish a method for detecting blood pressure and assess whether it could increase the OH detection rate in the elderly.

Methods: From May to October, 2022, 178 patients with symptomatic OH and 286 subjects with asymptomatic OH were selected. BP from the bilateral brachial artery was measured using two electronic sphygmomanometers on both arms at the same time, in the order of supine, sitting, and standing at 0-3 min. OH should meet 20/10 mmHg, standing BP minus sitting BP. The OH detection rates were calculated and compared. The symptomatic OH group was more often older, slimmer, had lower ADL scores, and contained fewer smokers (all P< 0.05).

Results: The detection rate of the symptomatic OH group using the modified method was 59.55%, which was higher than that of the routine method (34.83% vs. 59.55%, P<0.05). The detection rate using the modified method in the OH group with asymptomatic OH was 20.63%, which was higher than that of the routine method (20.63% vs. 5.59%, P< 0.01).

Conclusion: Synchronous measurement of bilateral brachial artery BP in supine, sitting, and standing positions increased the detection rate of OH in the elderly.

背景:直立性低血压(OH)是一种常见的临床体征,但其检出率较低,而且由于没有标准化的筛查方法,很难重复筛查。目的:本研究旨在建立一种检测血压的方法,并评估该方法能否提高老年人OH的检出率:方法:2022 年 5 月至 10 月,选取了 178 名有症状的 OH 患者和 286 名无症状的 OH 患者。使用两台电子血压计同时测量双侧肱动脉血压,测量顺序为仰卧、坐位、站位,测量时间为 0-3 分钟。OH 值应达到 20/10 mmHg,即站立血压减去坐位血压。计算并比较了 OH 的检出率。结果显示,无症状OH组年龄更大、体型更瘦、ADL评分更低、吸烟者更少(均P<0.05):结果:采用改良方法的无症状 OH 组的检出率为 59.55%,高于常规方法(34.83% 对 59.55%,P<0.05):在仰卧位、坐位和站立位同步测量双侧肱动脉血压可提高老年人 OH 的检出率。
{"title":"Synchronous Bilateral Brachial Blood Pressure Measurements Increased Orthostatic Hypotension Detection in the Elderly.","authors":"Jianying Zhang, Xia Gao, Benxu Ma, Lili Liu, Huanmin Gao","doi":"10.2174/0115734021269751231204114902","DOIUrl":"10.2174/0115734021269751231204114902","url":null,"abstract":"<p><strong>Background: </strong>Orthostatic hypotension (OH) is a common clinical sign, but its detection rate is low, and it is difficult to repeat because there is no standardized screening method available.</p><p><strong>Aim: </strong>This study aimed to establish a method for detecting blood pressure and assess whether it could increase the OH detection rate in the elderly.</p><p><strong>Methods: </strong>From May to October, 2022, 178 patients with symptomatic OH and 286 subjects with asymptomatic OH were selected. BP from the bilateral brachial artery was measured using two electronic sphygmomanometers on both arms at the same time, in the order of supine, sitting, and standing at 0-3 min. OH should meet 20/10 mmHg, standing BP minus sitting BP. The OH detection rates were calculated and compared. The symptomatic OH group was more often older, slimmer, had lower ADL scores, and contained fewer smokers (all P< 0.05).</p><p><strong>Results: </strong>The detection rate of the symptomatic OH group using the modified method was 59.55%, which was higher than that of the routine method (34.83% vs. 59.55%, P<0.05). The detection rate using the modified method in the OH group with asymptomatic OH was 20.63%, which was higher than that of the routine method (20.63% vs. 5.59%, P< 0.01).</p><p><strong>Conclusion: </strong>Synchronous measurement of bilateral brachial artery BP in supine, sitting, and standing positions increased the detection rate of OH in the elderly.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"57-63"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139058878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Hypertension in Children. 治疗儿童高血压。
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021305332240712103602
Francesca Mainieri, Veronica Maria Tagi, Francesco Chiarelli

Hypertension is a real problem in children. It shows a tracking behaviour, representing a key risk factor for hypertension, cardiovascular disease, and end-organ failure in adulthood. However, the importance of addressing arterial hypertension in children is not limited to its risk of tracking into adulthood. Thus, early detection and management are crucial. Hypertension may be primary or due to secondary causes, and identification of this distinction is very important for the treatment setting. Importantly, the management of hypertension in children is crucial to prevent the well-known cardiovascular effects in adulthood. As demonstrated in the literature, healthy eating habits, together with regular physical activity, can have a major impact on reducing high blood pressure and preventing organ damage in children and adolescents. However, suppose these are not sufficient to treat hypertension. In that case, if patients are symptomatic and/or have additional metabolic conditions such as obesity, type diabetes mellitus, or chronic kidney disease, anti-hypertensive medication must be started. Recent guidelines have provided clear guidance on the treatment of hypertension and hypertensive crisis in pediatric age. On the other hand, there are currently few specific recommendations on the treatment of isolated nocturnal hypertension and treatment- resistant hypertension. This review aims to summarize the most recent recommendations for the treatment of hypertension and hypertensive crisis in children and the last years' knowledge and experience in treating childhood isolated nocturnal hypertension and resistant hypertension of childhood.

高血压是儿童面临的一个现实问题。它具有追踪行为,是成年后高血压、心血管疾病和内脏衰竭的关键风险因素。然而,解决儿童动脉高血压问题的重要性并不仅限于其成年后的追踪风险。因此,早期发现和管理至关重要。高血压可能是原发性的,也可能是继发性的,识别这种区别对治疗非常重要。重要的是,儿童高血压的管理对于预防成年后众所周知的心血管影响至关重要。文献表明,健康的饮食习惯和有规律的体育锻炼对降低儿童和青少年的高血压和预防器官损伤有重要影响。然而,假设这些还不足以治疗高血压。在这种情况下,如果患者有症状和/或伴有其他代谢疾病,如肥胖、糖尿病或慢性肾病,就必须开始服用抗高血压药物。最近的指南为治疗儿科高血压和高血压危象提供了明确的指导。另一方面,目前几乎没有关于治疗孤立性夜间高血压和耐药性高血压的具体建议。本综述旨在总结治疗儿童高血压和高血压危象的最新建议,以及过去几年治疗儿童孤立性夜间高血压和儿童耐药性高血压的知识和经验。
{"title":"Treatment of Hypertension in Children.","authors":"Francesca Mainieri, Veronica Maria Tagi, Francesco Chiarelli","doi":"10.2174/0115734021305332240712103602","DOIUrl":"10.2174/0115734021305332240712103602","url":null,"abstract":"<p><p>Hypertension is a real problem in children. It shows a tracking behaviour, representing a key risk factor for hypertension, cardiovascular disease, and end-organ failure in adulthood. However, the importance of addressing arterial hypertension in children is not limited to its risk of tracking into adulthood. Thus, early detection and management are crucial. Hypertension may be primary or due to secondary causes, and identification of this distinction is very important for the treatment setting. Importantly, the management of hypertension in children is crucial to prevent the well-known cardiovascular effects in adulthood. As demonstrated in the literature, healthy eating habits, together with regular physical activity, can have a major impact on reducing high blood pressure and preventing organ damage in children and adolescents. However, suppose these are not sufficient to treat hypertension. In that case, if patients are symptomatic and/or have additional metabolic conditions such as obesity, type diabetes mellitus, or chronic kidney disease, anti-hypertensive medication must be started. Recent guidelines have provided clear guidance on the treatment of hypertension and hypertensive crisis in pediatric age. On the other hand, there are currently few specific recommendations on the treatment of isolated nocturnal hypertension and treatment- resistant hypertension. This review aims to summarize the most recent recommendations for the treatment of hypertension and hypertensive crisis in children and the last years' knowledge and experience in treating childhood isolated nocturnal hypertension and resistant hypertension of childhood.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"80-89"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141761601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights from the New European Society of Hypertension Guidelines Document. 欧洲高血压学会新指南文件要点。
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021309169240508110407
Guido Grassi

The present editorial will review the main recommendations included in the recent guidelines for the diagnosis and treatment of hypertension issued by the European Society of Hypertension. Emphasis will be given to some crucial issues of major relevance for current clinical practice, such as office and out-of-office blood pressure measurements, blood pressure threshold and targets, combination drugs, the position of beta-blocking drugs in the therapeutic intervention, and renal denervation.

本社论将回顾欧洲高血压学会最近发布的高血压诊断和治疗指南中的主要建议。重点将放在与当前临床实践密切相关的一些关键问题上,如诊室和诊室外血压测量、血压阈值和目标值、联合用药、β-阻断药物在治疗干预中的地位以及肾脏去神经支配。
{"title":"Highlights from the New European Society of Hypertension Guidelines Document.","authors":"Guido Grassi","doi":"10.2174/0115734021309169240508110407","DOIUrl":"10.2174/0115734021309169240508110407","url":null,"abstract":"<p><p>The present editorial will review the main recommendations included in the recent guidelines for the diagnosis and treatment of hypertension issued by the European Society of Hypertension. Emphasis will be given to some crucial issues of major relevance for current clinical practice, such as office and out-of-office blood pressure measurements, blood pressure threshold and targets, combination drugs, the position of beta-blocking drugs in the therapeutic intervention, and renal denervation.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"66-69"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statin Therapy and Flow-Mediated Dilation: A Systematic Review and Dose-Response Meta-Analysis Using the GRADE of Data from Randomized Controlled Trials. 他汀类药物治疗与血流介导的扩张:使用随机对照试验数据 GRADE 进行的系统回顾和剂量反应元分析
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021280797240212091416
Seyyed Mostafa Arabi, Mahla Chambari, Leila Sadat Bahrami, Saeid Hadi, Amirhossein Sahebkar

Introduction: A previous meta-analysis reported the positive effects of statin therapy on endothelial function. However, the obtained result had several limitations that necessitated updating the information in this field. Therefore, a systematic and meta-analysis review was conducted to determine whether statin therapy could improve endothelial function, as assessed by flow-- mediated dilation (FMD).

Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science were searched to identify randomized placebo-controlled trials assessing the impact of statin therapy on FMD. A random-effects model was used for meta-analysis to calculate the mean difference in weight. Meta- regression and subgroup analyses were used to identify sources of heterogeneity. In addition, nonlinear dose-response, quality of evidence, influence analysis, and publication bias evaluation were assessed using standard methods.

Result: Thirty-five trials (41 arms) involving 2178 participants were included in the meta-analysis study. Statin treatment significantly improved FMD [weighted mean difference (WMD): 1.7%, 95% CI: 1.3-2.2, p < 0.001). However, significant heterogeneity was observed (I2=97.9%, p < 0.001). The results of the subgroup analysis showed that health status can contribute to heterogeneity. Non-linear dose-response analysis revealed the most significant improvement in FMD with atorvastatin at a dose of 20 mg/day and simvastatin at 80 mg/day.

Conclusion: Statin therapy significantly improved endothelial function, as assessed by FMD. These changes are clinically significant, but their use should be approached with caution.

导言之前的一项荟萃分析报告了他汀类药物治疗对内皮功能的积极影响。然而,所获得的结果存在一些局限性,因此有必要更新这一领域的信息。因此,我们进行了一项系统性荟萃分析综述,以确定他汀类药物治疗是否能改善内皮功能,该功能通过血流介导的扩张(FMD)进行评估:方法:检索了MEDLINE、SciVerse Scopus和Clarivate Analytics Web of Science,以确定评估他汀类药物治疗对FMD影响的随机安慰剂对照试验。荟萃分析采用随机效应模型计算体重的平均差异。元回归和亚组分析用于确定异质性的来源。此外,还使用标准方法评估了非线性剂量反应、证据质量、影响分析和发表偏倚评价:荟萃分析研究共纳入 35 项试验(41 项研究),涉及 2178 名参与者。他汀类药物治疗可明显改善 FMD [加权平均差(WMD):1.7%,95% CI:1.3-2.2,P < 0.001]。然而,观察到了明显的异质性(I2=97.9%,p < 0.001)。亚组分析结果表明,健康状况可能导致异质性。非线性剂量反应分析显示,阿托伐他汀剂量为20毫克/天时,FMD的改善最为显著;辛伐他汀剂量为80毫克/天时,FMD的改善最为显著:结论:他汀类药物治疗可明显改善内皮功能(以 FMD 评估)。结论:他汀类药物能明显改善血管内皮功能(以 FMD 评估)。这些变化具有临床意义,但应谨慎使用。
{"title":"Statin Therapy and Flow-Mediated Dilation: A Systematic Review and Dose-Response Meta-Analysis Using the GRADE of Data from Randomized Controlled Trials.","authors":"Seyyed Mostafa Arabi, Mahla Chambari, Leila Sadat Bahrami, Saeid Hadi, Amirhossein Sahebkar","doi":"10.2174/0115734021280797240212091416","DOIUrl":"10.2174/0115734021280797240212091416","url":null,"abstract":"<p><strong>Introduction: </strong>A previous meta-analysis reported the positive effects of statin therapy on endothelial function. However, the obtained result had several limitations that necessitated updating the information in this field. Therefore, a systematic and meta-analysis review was conducted to determine whether statin therapy could improve endothelial function, as assessed by flow-- mediated dilation (FMD).</p><p><strong>Methods: </strong>MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science were searched to identify randomized placebo-controlled trials assessing the impact of statin therapy on FMD. A random-effects model was used for meta-analysis to calculate the mean difference in weight. Meta- regression and subgroup analyses were used to identify sources of heterogeneity. In addition, nonlinear dose-response, quality of evidence, influence analysis, and publication bias evaluation were assessed using standard methods.</p><p><strong>Result: </strong>Thirty-five trials (41 arms) involving 2178 participants were included in the meta-analysis study. Statin treatment significantly improved FMD [weighted mean difference (WMD): 1.7%, 95% CI: 1.3-2.2, p < 0.001). However, significant heterogeneity was observed (I<sup>2</sup>=97.9%, p < 0.001). The results of the subgroup analysis showed that health status can contribute to heterogeneity. Non-linear dose-response analysis revealed the most significant improvement in FMD with atorvastatin at a dose of 20 mg/day and simvastatin at 80 mg/day.</p><p><strong>Conclusion: </strong>Statin therapy significantly improved endothelial function, as assessed by FMD. These changes are clinically significant, but their use should be approached with caution.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"90-100"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening for Hypertension in Adults of a Northern Delta Province in Vietnam. 越南北部三角洲省成人高血压筛查。
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-01-01 DOI: 10.2174/0115734021283836240522120929
Minh Huynh Van, Thuy Le Thi Bich, Nguyen Tran Tu, Sang Phan Van, Yen Hoang Thị Bạch, Tien Hoang Anh

Background: The proportion of people with hypertension is increasing, and those affected are relatively younger. Worldwide, it is estimated that people with high blood pressure are more than 1.5 billion people. In Vietnam, from 2002 to 2008, according to a national survey on hypertension and its risk factors within the prevention and control of cardiovascular disease program, the prevalence of hypertension was 25.1%. This is alarming because high blood pressure can cause serious complications, including death.

Objective: The study aimed to explore the blood pressure characteristics and hypertension prevalence in adults in a northern delta province of Vietnam, and describe some risk factors in hypertensive subjects screened through the program.

Methods: This was a cross-sectional study collecting data from people aged 18 years or older in 10 cantons and the city of Nam Dinh from July 15th to July 31st, 2020. Using semi-automatic OMRON sphygmomanometers, sitting blood pressure was measured three times according to standardized methods specified by the Ministry of Health and two National Vascular Societies.

Results: Blood pressure screening of 183,632 adults included 84,438 males, which accounted for 45.98%, with an average age of 60.36 ± 13.18 years. The estimated prevalence of hypertension was 27.20% (95% CI: 27.00% - 27.41%). The older the age, the higher the rate of hypertension in both sexes; the prevalence of hypertension over 65 years was 45.36%. Hypertension grade 1 accounted for 17.14%, followed by hypertension at grade 2 at 6.69%, and grade 3 at 1.15%; notably, the percentage of prehypertension accounted for 49.64%. The percentage of treated hypertension in Nam Dinh province was 56.85%, but the percentage of uncontrolled hypertension was 85.63%.

Conclusion: The prevalence of hypertension in Nam Dinh province was relatively high (27.20%), although the number of treated patients was also high (56.85%); moreover, the proportion of uncontrolled hypertension remained extremely high (85.63%). Local campaigns and suitable interventions are required to detect hypertension in the early stages and increase awareness for treatment in the population.

背景:高血压患者的比例正在增加,而且患者相对年轻。据估计,全世界高血压患者超过 15 亿人。在越南,2002 年至 2008 年期间,根据心血管疾病预防和控制计划中的一项关于高血压及其风险因素的全国调查,高血压患病率为 25.1%。这令人担忧,因为高血压可导致严重的并发症,包括死亡:本研究旨在探讨越南北部三角洲省成年人的血压特征和高血压患病率,并描述通过该计划筛查的高血压受试者的一些风险因素:这是一项横断面研究,收集了 2020 年 7 月 15 日至 7 月 31 日期间 10 个县和南定市 18 岁及以上人群的数据。使用半自动欧姆龙血压计,按照卫生部和两个国家血管协会规定的标准化方法测量三次坐位血压:对 183 632 名成年人进行了血压筛查,其中男性 84 438 人,占 45.98%,平均年龄为 60.36 ± 13.18 岁。高血压患病率估计为 27.20%(95% CI:27.00% - 27.41%)。年龄越大,男女高血压患病率越高;65 岁以上高血压患病率为 45.36%。一级高血压占 17.14%,二级高血压占 6.69%,三级高血压占 1.15%;值得注意的是,高血压前期占 49.64%。南定省接受治疗的高血压患者占 56.85%,但未得到控制的高血压患者占 85.63%:结论:南定省的高血压发病率相对较高(27.20%),但接受治疗的患者人数也较多(56.85%);此外,未得到控制的高血压比例仍然极高(85.63%)。需要在当地开展宣传活动并采取适当的干预措施,以便在早期阶段发现高血压并提高民众的治疗意识。
{"title":"Screening for Hypertension in Adults of a Northern Delta Province in Vietnam.","authors":"Minh Huynh Van, Thuy Le Thi Bich, Nguyen Tran Tu, Sang Phan Van, Yen Hoang Thị Bạch, Tien Hoang Anh","doi":"10.2174/0115734021283836240522120929","DOIUrl":"10.2174/0115734021283836240522120929","url":null,"abstract":"<p><strong>Background: </strong>The proportion of people with hypertension is increasing, and those affected are relatively younger. Worldwide, it is estimated that people with high blood pressure are more than 1.5 billion people. In Vietnam, from 2002 to 2008, according to a national survey on hypertension and its risk factors within the prevention and control of cardiovascular disease program, the prevalence of hypertension was 25.1%. This is alarming because high blood pressure can cause serious complications, including death.</p><p><strong>Objective: </strong>The study aimed to explore the blood pressure characteristics and hypertension prevalence in adults in a northern delta province of Vietnam, and describe some risk factors in hypertensive subjects screened through the program.</p><p><strong>Methods: </strong>This was a cross-sectional study collecting data from people aged 18 years or older in 10 cantons and the city of Nam Dinh from July 15th to July 31st, 2020. Using semi-automatic OMRON sphygmomanometers, sitting blood pressure was measured three times according to standardized methods specified by the Ministry of Health and two National Vascular Societies.</p><p><strong>Results: </strong>Blood pressure screening of 183,632 adults included 84,438 males, which accounted for 45.98%, with an average age of 60.36 ± 13.18 years. The estimated prevalence of hypertension was 27.20% (95% CI: 27.00% - 27.41%). The older the age, the higher the rate of hypertension in both sexes; the prevalence of hypertension over 65 years was 45.36%. Hypertension grade 1 accounted for 17.14%, followed by hypertension at grade 2 at 6.69%, and grade 3 at 1.15%; notably, the percentage of prehypertension accounted for 49.64%. The percentage of treated hypertension in Nam Dinh province was 56.85%, but the percentage of uncontrolled hypertension was 85.63%.</p><p><strong>Conclusion: </strong>The prevalence of hypertension in Nam Dinh province was relatively high (27.20%), although the number of treated patients was also high (56.85%); moreover, the proportion of uncontrolled hypertension remained extremely high (85.63%). Local campaigns and suitable interventions are required to detect hypertension in the early stages and increase awareness for treatment in the population.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"101-108"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Hypertension Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1